Active ad and exact outbound link observed in Meta Ad Library on October 22, 2026. The page image and section source are the existing October 20 capture of this destination. Offers and product selections may change. Selection reflects creative and page structure; performance is not available.

She looked into Ozempic · editorial-style creative. The creator’s opening promise continues into an editorial introduction, repeated purchase options, customer stories, and FAQs. Compare the creative with the destination and explore the other ads sharing this route.
Selected for its design and offer structure. Ad performance isn’t available in this collection.
The ad doesn't look like an ad. The article frame, with a share button and a news-style headline under a portrait, borrows the feel of a story someone sent you, which earns a tap from people who skip product shots. The headline is a narrative with a turn in it (she looked into one thing and found another), so the viewer wants the rest of the story. And the click delivers on the format: it opens an advertorial, so the article feel continues instead of dropping into a shop page. The brand ran several versions of this creative.
The copy under the image is the weakest part. It says WLP-1 brings a new option for weight management without needles, which is broad enough for any brand in the category, and it adds nothing the headline didn't already say. The ad never says who the woman is or what she found specifically, so the story stays a teaser. If you make one like this, put one concrete detail from the article in the copy (the two-capsules-before-your-biggest-meal routine, or the refund promise) so the viewer clicks for a reason, not only out of curiosity.
The editorial look makes the ad feel like content someone shared rather than a promotion.
A story with a turn creates curiosity about what she found and how.
It names the product and the category so the click makes sense.
It sends people to the needle-free GLP-1 advertorial, a focused editorial page, which is the right next step for an article-style ad. The hero, Skip the shot, claims WLP-1 boosts the body's own GLP-1 by up to 321% and lists fuller longer, cravings quiet down and burn more at rest. Then Five reasons why people are choosing the injection-free route walks through no needles or prescription, absorption, three pathways, side effects and the two-capsule routine, before What customers report, the product block, FAQs and a refund promise. Message match is strong: the ad sets up a story and the page reads like the rest of it. It's one of 10 ads in the Fluid library pointing here.
An advertorial for WLP-1 that frames the product as a needle-free route, with a co-founder byline, three benefit tiles, an early plan box, five numbered reasons, customer reports, FAQs and a refund guarantee. 10 Absorption Company ads in the Fluid library link here, mainly editorial-style statics and creator videos about no needles and no prescription.
States the GLP-1 claim, the no-needle framing and the price-from line with a study disclaimer, answering what this is and why read on.
Opens in the co-founders' voice with the brand's case against injections, answering who is talking and what problem they see.
Names fullness, quieter cravings and burning more at rest, answering what the product is claimed to do.
Offers 3-month, 6-month and monthly plans with badges and the guarantee, answering how to buy right away.
Numbered sections on cost, absorption, three pathways, side effects and the routine, answering the main objections one at a time.
Shares what customers report, answering whether people like the reader have tried it.
Restates WLP-1 with its plans, answering how to order after reading.
Covers remaining questions, answering the last doubts before purchase.
Promises a refund if it doesn't work, with free shipping and cancel-anytime tiles, answering what happens if it doesn't suit you.
Read the full breakdown of this page
One of 188 The Absorption Company ads in the Fluid Inspiration Library, captured from the Meta Ad Library on Oct 22, 2026. We record that an ad ran publicly, not how it performed.